Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
Cardiol Therapeutics Inc. (
a clinical-stage biotechnology company
focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management s Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company s profile on SEDAR at www.sedar.com and on the Company s website at www.cardiolrx.com.
David Elsley, President and Chief Executive Officer of Cardiol, commented: 2020 was a very exciting year for Cardiol Therapeutics. We made extraordinary progress in our research and clinical development programs, while significantly strengthening our financial position. We are particularly excited about the progress made across our research and development programs supporting the development of CardiolRx, our pharmaceutically produced extra-strength oral f
Cardiol Therapeutics Inc.: Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company s Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Oakville, Ontario (Newsfile Corp. - December 15, 2020) - Cardiol Therapeutics Inc. (
TSX: CRDL) (
Cardiol or the
Company ), a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ( CVD ), announces that it has appointed contract research organization ( CRO ) Worldwide Clinical Trials ( Worldwide ), as the Company initiates it s Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States. The double-blind, placebo-controlled clinical trial is designed to investigate the efficacy and safety of CardiolRx, a pharmaceutically produced extra strength cannabidiol formulation, in 422 hospitalized COVID-19 patients with a prior history of, or